Cardiology Update

AUGUST 4, 2024

Despite proven benefits in reducing morbidity and mortality, many heart failure (HF) patients do not receive optimal guideline-directed medical therapy (GDMT). This includes beta-blockers, ACE inhibitors, ARBs, ARNIs, MRAs, and SGLT2 inhibitors. ESC Heart Failure 2024; 11 : 560–569.

Heart Failure 119

Heart Failure ACE Inhibitor COVID-19 Quality of Life 119

DAIC

APRIL 6, 2024

However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. All secondary endpoints related specifically to heart failure outcomes were significantly reduced among patients who received empagliflozin.

Heart Attack 98

Heart Attack Heart attacks Heart Failure Outpatient 98

DAIC

APRIL 6, 2024

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,

Heart Attack 81

Heart Attack Heart attacks Heart Failure Outcomes 81

Open Heart

FEBRUARY 17, 2024

Objective To evaluate stress, depression and quality of life among community-dwelling patients with heart failure (HF) and evaluate their effect on perceived medication adherence in a socioeconomically challenged setting. were on ACE inhibitors/angiotensin receptor blockers and 54.9% The mean age was 61.3±17.36

Heart Failure 40

Heart Failure Quality of Life ACE Inhibitor COVID-19 40